Novo drug ziltivekimab meets primary endpoint in inflammatory biomarker trial

According to Novo Nordisk, the trial showed a significant reduction in several inflammatory biomarkers associated with atherosclerosis in people with advanced chronic kidney disease.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk has released the results of its phase II trial of ziltivekimab, 'Rescue'. The drug, which is taken monthly, attained its primary goal of reducing inflammatory biomarkers associated with atherosclerosis (hardened arteries, -ed.) in people with advanced chronic kidney disease.

The press release written by Novo Nordisk states that the data was released at the American College of Cardiology's 70th annual conference (this year, a virtual conference) and published in the Lancet.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs